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Abstract
Background: Hematologic toxicity represents a major side effect of cytotoxic chemotherapy frequently preventing
adequately dosed chemotherapy application and impeding therapeutic success. Transgenic (over)expression of
chemotherapy resistance (CTX-R) genes in hematopoietic stem- and progenitor cells represents a potential strategy
to overcome this problem. To apply this concept in the context of acute myeloid leukemia and myelodysplasia, we
have investigated the overexpression of the multidrug resistance 1 (MDR1) and the cytidine deaminase (CDD) gene
conferring resistance to anthracyclines and cytarabine (Ara-C), the two most important drugs in the treatment of
these diseases.
Methods: State-of-the-art, third generation, self-inactivating (SIN) lentiviral vectors were utilized to overexpress a
human CDD-cDNA and a codon-optimized human MDR1-cDNA corrected for cryptic splice sites from a spleen
focus forming virus derived internal promoter. Studies were performed in myeloid 32D cells as well as primary
lineage marker negative (lin−) murine bone marrow cells and flow cytometric analysis of suspension cultures and
clonogenic analysis of vector transduced cells following cytotoxic drug challenge were utilized as read outs.
Results: Efficient chemoprotection of CDD and MDR1 transduced hematopoietic 32D as well as primary lin− cells
was proven in the context of Ara-C and anthracycline application. Both, CTX-R transduced 32D as well as primary
hematopoietic cells displayed marked resistance at concentrations 5–20 times the LD50 of non-transduced control
cells. Moreover, simultaneous CDD/MDR1 gene transfer resulted in similar protection levels even when combined
Ara-C anthracycline treatment was applied. Furthermore, significant enrichment of transduced cells was observed
upon cytotoxic drug administration.
Conclusions: Our data demonstrate efficient chemoprotection as well as enrichment of transduced cells in
hematopoietic cell lines as well as primary murine hematopoietic progenitor cells following Ara-C and/or anthracycline
application, arguing for the efficacy as well as feasibility of our approach and warranting further evaluation of
this concept.
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Background
Cytotoxic chemotherapy represents a major component
of anti-cancer treatment strategies. However, cytotoxic
agents not only affect the malignant target cells, but also
are associated with substantial damage to healthy cells
and tissues. In particular hematologic toxicity represents
a major and frequently dose-limiting side effect that may
cause severe infectious complications and thrombocyto-
penias, prohibit further application of chemotherapy on
time, and impede therapeutic success. Transgenic (over)-
expression of chemotherapy resistance (CTX-R) genes in
hematopoietic stem- and progenitor cells, also referred
to as chemo- or myeloprotective gene therapy, represents
a potential strategy to overcome this problem [1, 2]. In this
regard, a number of CTX-R genes have been identified and
studied for their myeloprotective properties [1]. Of note,
recently effective protection from alkylating agent-induced
myelotoxicity has been demonstrated following gene
transfer of the CTX-R gene mutant O6-methylguanine
methyltransferase (mutMGMT) in a cohort of glioblast-
oma patients treated with temozolomide [3, 4]. In this
study, profound in vivo enrichment of genetically modified
hematopoietic cells and clinical benefits in comparison to
a disease matched control group was demonstrated, estab-
lishing a proof-of-concept for the clinical applicability and
efficacy of myeloprotective gene therapy approaches.
Other myeloprotective strategies interfere with antimetab-
olite type cytotoxic drugs. This includes mutant forms of
dihydrofolate reductase (mutDHFR), protecting cells from
antifolate drugs such as methotrexate and trimetrexate
[5–7] as well as knock-down of hypoxanthine phosphori-
bosyl transferase (HPRT) expression protecting cells from
purine analogs like 6-thioguanine [8].
Multi-drug resistance 1 (MDR1) and cytidine deaminase
(CDD) represent two other well-studied CTX-R genes.
The human MDR1 gene encodes the cellular efflux
protein ABCB1 (P-glycoprotein, P-gp), a member of
the ATP-binding cassette superfamily, which confers
resistance to a wide variety of clinically relevant chemother-
apeutic agents including anthracyclines, epipodophyllotox-
ins, taxoids or vinca-alkaloids [9]. Transgenic expression of
MDR1 by γ-retroviral vectors protects murine and human
hematopoietic cells from the toxic effects of paclitaxel, vin-
cristine, etoposide, doxorubicin or daunorubicin in vitro
[10–15]. Moreover, for various of these agents in vivo pro-
tection of murine and human hematopoietic cells has been
demonstrated following γ-retroviral gene-transfer to HSCs
in murine [10, 16–18] and humanized (NOD/SCID) [19]
transplant models, respectively, and chemoprotection of
human hematopoietic progenitor cells in vitro also has
been reported following lentiviral mediated gene transfer of
MDR1 [20, 21]. Furthermore, MDR1 has been successfully
used as a selection marker during hematopoietic stem cell
gene therapy (HSC-GT) [18, 22]. Despite these pre-clinical
achievements early clinical trials with MDR1 in the late
1990s showed only moderate success primarily due to low
gene transfer efficacy [23–27] or aberrant splicing of the
MDR1 gene [28]. CDD codes for an enzyme of the
nucleotide salvage pathway and protects cells against
such clinically relevant agents as cytosine-arabinoside
(Ara-C), gemcitabine, decitabine and azacytidine [29].
Meanwhile, CDD-mediated drug resistance and enrichment
of transduced cells following γ-retroviral gene transfer has
been established in murine and human hematopoietic cells
in vitro [30–32] as well as murine long-term reconstituting
hematopoietic stem cells (HSC) [33, 34]. Though, a poten-
tial lymphotoxicity of CDD overexpression was noted in
one of these studies [34], this problem was circumvented
when doxycycline-induced transgene expression from a
lentiviral vector backbone was employed [35].
Combinations of Ara-C and anthracyclines as in the
classical “3 + 7” or TAD regimen [36] are highly effective
in the treatment of acute myeloid leukemia or high-risk
myelodysplasia and represent the backbone of chemo-
therapy in these disease entities. However, these regi-
mens are associated with a profound and long-lasting
myelosuppression. This may create problems particularly
in relapsed disease situations and/or in the elderly,
where an already compromised hematopoietic stem cell
compartment even aggravates these side effects. To
overcome this dilemma hematopoietic stem cell gene
therapy allowing for the combined overexpression of
CDD and MDR1 appears as a logical strategy to protect
the lymphohematopoietic system from combined chemo-
therapy. Thus, we here have evaluated this concept apply-
ing state-of-the-art lentiviral gene transfer technology.
Our data demonstrate highly efficient chemoprotection as
well as enrichment of transduced cells in hematopoietic
cell lines as well as primary murine hematopoietic
progenitor cells following combined Ara-C/anthracycline
application.
Methods
Lentiviral vector constructs and preparations
Lentiviral vectors were based on 3rd generation SIN lenti-
viral vectors modified with a woodchuck hepatitis virus-
derived xposttranscriptional-regulatory element [37, 38].
RRL.PPT.SFFV.hMDR1.IRES.GFPpre* (referred to as
LV.SFFV.MDR1) contained a human codon-optimized
multidrug resistance gene 1 (hMDR1) cDNA additionally
modified by removing (cryptic) splice donor and acceptor
sites to increase tRNA usage and thereby increase ex-
pression levels. The hMDR1-cDNA was inserted with
AgeI/SalI restriction enzymes into RRL.PPT.SFFV.pre*
construct. Subsequently, an enhanced green fluores-
cent protein (eGFP) was inserted together with an
IRES site via SalI. RRL.PPT.SFFV.hCDD.IRES.GFP.pre*
and RRL.PPT.SFFV.hCDD.IRES.dtomato.pre* (referred
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to as LV.SFFV.CDD) were generated by cloning of the
cDNA of human cytidine deaminase (hCDD) (former
OpenBiosystems, IHS1380-OB-97652440, Epsom, UK)
via AgeI/SalI followed by SalI mediated insertion of an IRES
site linked to a green (GFP) or red (dtomato) fluorescent
protein. RRL.PPT.SFFV.hCDD.P2A.hMDR1.IRES.GFP.pre*
(referred to as LV.SFFV.CDD.2A.MDR1) was generated by
insertion of hCDD and hMDR1 and a porcine teschovirus-
1 (P2A) linker sequence using overlap/extension PCR.
Subsequently, the hCDD fragment was inserted into
LV.SFFV.MDR1 by AgeI followed by introduction of
IRES.GFP via SalI. RRL.PPT.SFFV.GFP.pre* (referred to as
LV.SFFV.GFP) was cloned by insertion of GFP reporter into
RRL.PPT.SFFV.pre*. Production as well as titration was
performed as previously described [39]. Titers (TU/mL)
ranged from 2×106 - 9×106 for LV.SFFV.MDR1,
1×106 - 1×107 for LV.SFFV.CDD.2A.MDR1, 3×107 - 2×108
for LV.SFFV.CDD, and 2×107 - 2×108 for LV.SFFV.GFP
control vector.
Experiments with 32D myeloid cells
Culture
Murine 32D cells were cultured in RPMI-1640 supple-
mented with 10 % fetal calf serum (Biochrom, Berlin,
Germany), 100 U/ml penicillin/streptomycin (Pen/Strep),
2 mmol/l glutamine (all Life Technologies) and 2 ng/ml
mIL-3 (Peprotech, Hamburg, Germany).
Transduction
Genetic modification of 32D cells was performed by
adding viral supernatant to cells in the presence of
10 μg/ml protaminsulfate (Carl Roth, Karlsruhe, Germany)
at 37 °C. Twenty-four hours after transduction, cells
were washed, expanded for several days and subsequently
sorted for fluorescent reporter gene expression (FACS
AriaIIu, Becton Dickinson) to establish transgenic
32D cells of purity ≥ 90 %.
In vitro protection
Chemoprotection was carried out by seeding 1.5×105
cells in 2 ml complete medium and cytotoxic drugs were
added in given concentrations. Following three days in-
cubation, cell survival was analyzed by flow cytometry
(using FSC/SSC exclusion). Stock solutions of cytotoxic
drugs were prepared by central pharmacy of Hannover
Medical School.
Transgene expression analysis
To analyze expression of hMDR1, RNA was isolated
from cells previously treated with cytotoxic drugs as well
as non-treated controls using TRIsure reagent (Bioline,
London, UK) as recommended by the manufacturer.
Following DNase I digestion, RNA was reverse transcribed
using RevertAid reverse transcriptase and oligo(dT)
primers (all Thermo Scientific, Schwerte, Germany).
Subsequently, 25 ng cDNA was used for quantification by
SYBR Green-based qRT-PCR on a StepOnePlus Real-
Time PCR System (Thermo Scientific, Schwerte, Germany
Biosystems). Expression of hDMR1 mRNA is given rela-
tive to non-treated untransduced control cells (normalized
to endogenous murine β-actin). Expression of hCDD pro-
tein was analyzed by Western Blot as described previously
[40] using cells previously treated with cytotoxic drugs as
well as non-treated controls.
In vitro proliferation assay
Cell proliferation analysis of (transduced) 32D cells was
determined using cell proliferation dye eFluor 670
(eBioscience, San Diego, CA, USA). In brief, cells were
incubated with the proliferation dye as recommended by
the manufacturer and analyzed for initial dye uptake
using flow cytometry (FL4 channel, FACS Calibur,
Becton Dickinson). Subsequently, cells were applied to
an in vitro protection assay as described above and three
days later analyzed by flow cytometry.
Experiments with primary murine hematopoietic cells
Isolation
Bone marrow of C57BL/6 (Janvier Laboratories, Saint
Berthevin Cedex, France and Central animal facility,
Hannover Medical School, Hannover, Germany) mice
was harvested from femora and tibiae and lineage nega-
tive (lin−) cells were purified using MACS separation
(Lineage Cell depletion kit, Miltenyi, Bergisch Gladbach,
Germany). Cells were cultured and prestimulated for 24 h
in StemSpan medium (StemCell Technologies, Cologne,
Germany) supplemented with 10 ng/ml rmSCF, 20 ng/ml
rmTPO, 20 ng/ml rmIGF and 10 ng/ml rhFGF (all
PeproTech) prior to transduction.
Transduction
Transduction of lin− cells with lentiviral vectors was
carried out using retronection (10 mg/cm2; Takara,
Otsu, Japan) -coated dishes as recommended by the
manufacturer. Approximately three to four days later,
non-sorted cells were applied to myeloid in vitro differ-
entiation experiments or cells were sorted for GFP re-
porter gene expression and subjected to a clonogenic
progenitor assays.
Clonogenic progenitor assays
Clonogenic growth of hematopoietic progenitor cells
were assessed by incubating 1.500 transduced lin- cells
previously sorted for eGFP expression. Clonogenic cul-
tures were performed in 1 ml IMDM/1.3 % methylcellu-
lose supplemented with 15 % fetal calf serum, 2 %
bovine serum albumin, 2 mM L-glutamine, 50 μM 2-
Mercaptoethanol, 10 μg/ml rh-insulin, 200 μg/ml human
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transferrin, 50 ng/ml rm-SCF, 10 ng/ml rm-IL3, 10 ng/ml
rm-IL6 and 5 IU/ml rh-EPO (HSC007, R&D Systems,
Wiesbaden-Nordenstadt, Germany) in the presence of
different concentrations of cytotoxic drugs. Colonies
of more than 50 cells were counted after 6–7 days.
Myeloid in vitro differentiation
In vitro protection and selection was performed using
5×104 non-sorted transduced lin− cells. Cells were cul-
tured in RPMI-1640 supplemented with 10 % fetal calf
serum, 100 U/ml penicillin/streptomycin (Pen/Strep),
2 mmol/l glutamine and addition of 20 ng/ml rmIL-3 and
100 ng/mL rh-G-CSF (Peprotech, Hamburg, Germany).
Cells were treated with cytotoxic drugs in the given con-
centration for three days and analyzed by flow cytometry.
For in vitro selection, data are given as fold increase in %
GFP+ cells with non-treated cells = 1.
Statistical analysis
All graphs were created using Prism V5 (GraphPad) and
statistical analysis was performed using Prism V6 soft-
ware (GraphPad, La Jolla, CA, USA). Unless otherwise
noted analysis of variance (ANOVA) with recommended
post hoc testing was performed.
Results
Generation of lentiviral vectors
To express CTX-R genes in hematopoietic target cells,
third generation SIN lentiviral vectors were generated.
Lentiviral constructs were equipped with a codon-
optimized version of the human multidrug resistance 1
gene (hMDR1) cDNA additionally corrected for cryptic
splice sites (LV.SFFV.MDR1) or a cDNA encoding for
human cytidine deaminase (hCDD; LV.SFFV.CDD) used
in combination with the fluorescence markers GFP or
dTomato. Simultaneous expression of hCDD and hMDR1
in hematopoietic cells was accomplished either by co-
transduction with two vectors (only in 32D cells) or by
transduction with a vector containing hCDD and hMDR1
linked via a porcine teschovirus-1 (P2A) linker sequence
(LV.SFFV.CDD.2A.MDR1). In all constructs transgene ex-
pression was driven by an internal spleen focus forming
virus (SFFV) promoter, and a vector solely expressing GFP
served as a control (Fig. 1).
Efficient protection of 32D cells from cytotoxic drug
treatment
To prove functionality of our lentiviral vectors, initial
experiments were carried out in murine myeloid 32D
cells. Median transduction rates of 32D cells as determined
by reporter expression were 16 % for LV.SFFV.MDR1,
6.7 % for LV.CDD.2A.MDR1, 43.5 % for LV.SFFV.CDD and
84 % for LV.SFFV.GFP. Following transduction cells were
enriched by fluorescence-activated cell sorting (FACS)
based on reporter gene expression to achieve populations
with ≥ 92 % purity. MDR1 and CDD transgene expression
in these populations were confirmed by qRT-PCR or
Western blot, respectively (Additional file 1: Figure S1).
Subsequently, cells were treated with chemotherapeutic
agents and first experiments were performed with vectors
carrying a single CTX-R gene. Here LV.SFFV.MDR1
gene-modified cells displayed a classical multi-drug resist-
ance phenotype demonstrated by significant protection
from typical MDR1-associated drugs including the
anthracyclines daunorubicin (≥125 nM) and doxorubicin
(≥250 nM) (Fig. 2a, Additional file 2: Figure S2A) as well
as the taxoid derivative paclitaxel and the epipodophyllo-
toxin etoposide (Additional file 2: Figure S2B,C). Of note,
for all four drugs, transgenic MDR1 expression conferred
profound chemoprotection with virtually 100 % cell survival
even at concentrations in excess of 5- (anthracyclines,
etoposide) or even 40-times (paclitaxel) the LD50 of not
transduced control cells. As expected, overexpression of
CDD using the LV.SFFV.CDD construct did not result
in protection against daunorubicin (Fig. 2a), however,
when Ara-C instead of daunorubicin was administered,
LV.SFFV.CDD gene-modified cells revealed significantly
increased chemoresistance (≥2000 nM) and were protected
from concentrations more than 5-times the LD50 of non-
transduced control or MDR1 gene-modified cells (Fig. 2b).
Next, we evaluated the functionality of combined
CDD/MDR1 expression in 32D cells. To this point, cells
were either co-transduced with the two single CTX-R
vectors (LV.SFFV.CDD and LV.SFFV.MDR1) or modified
with the LV.SFFV.CDD.2A.MDR1 vector expressing both
genes, CDD and MDR1, from a single construct. Again,
transgenic cells were enriched by FACS and thereafter
treated with daunorubicin or Ara-C. Both LV.SFFV.CDD/
LV.SFFV.MDR1 as well as LV.SFFV.CDD.2A.MDR1 gene-
modified cells were protected against daunorubicin mono-
therapy (≥125 nM), whereas control cells were susceptible
from 25 nM onwards (Fig. 2c). Similar results were
observed when cells were treated with Ara-C, except
for a slightly reduced resistance to very high Ara-C
concentrations (2000 nM) in LV.SFFV.CDD.2A.MDR1
transduced cells (Fig. 2d). Finally, cells expressing
CDD and MDR1 were treated with a combination of
daunorubicin and Ara-C. While non-transduced 32D
control cells were highly susceptible to all drug com-
binations applied, LV.SFFV.CDD/LV.SFFV.MDR1 as
well as LV.SFFV.CDD.2A.MDR1 gene-modified cells
demonstrated marked resistance to the daunorubicin/
Ara-C combination with > 80 % of cells surviving
even at the highest doses tested. Likewise percentages
of surviving cells were significantly increased ranging
from 17-100-fold for LV.SFFV.CDD/ LV.SFFV.MDR1
and 19-110-fold for LV.SFFV.CDD.2A.MDR1, respectively
(Fig. 2e).
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Results of these cytotoxicity studies were confirmed by
cell proliferation analysis of e670 labelled 32D cells. In
these studies susceptibility of 32D cells to daunorubicin
as well as Ara-C was clearly associated with cell cycle
arrest, whereas MDR1 or CDD transgene expression
reconstituted the proliferative potential of 32D cells also
in the presence of the respective drugs (Additional file 3:
Figure S3).
Therefore, our data clearly show that expression of
CDD and MDR1 alone or in combination results in in-
creased myeloprotection in the context of anthracycline
and/or nucleoside-analogue therapy.
Chemoprotection of primary hematopoietic progenitor cells
Next, we employed our lentiviral vectors in primary
murine hematopoietic progenitor cells. To this point, lin−
murine bone marrow cells were transduced and following
FACS-based enrichment for GFP expression, seeded into
clonogenic assays in the presence of cytotoxic drugs.
Median transduction rates of primary cells used for
clonogenic as well as suspension experiments (s. below)
as determined by GFP reporter expression were lower
for vectors containing MDR1 (4.6 % and 4.9 % for
LV.SFFV.MDR1 and LV.CDD.2A.MDR1, respectively) than
for LV.SFFV.CDD (49 %) and LV.SFFV.GFP control (50 %).
First, cells transduced with LV.SFFV.MDR1 were ana-
lyzed. As evident from Fig. 3a clonogenic growth from
these cells clearly was protected from the daunorubicin
treatment with virtually unperturbed colony growth ob-
served in the presence of up to 60 nM of the drug. In
contrast, colony growth of LV.SFFV.GFP and mock-
transduced control cells was significantly reduced already
from 30 nM daunorubicin onwards (Fig. 3a, Additional
file 4: Figure S4A). Similarly, survival of LV.SFFV.CDD
gene-modified cells was analyzed in the presence of
increasing concentrations of Ara-C. Again a profound
protection mediated by the CTX-R gene was detected.
While clonogenic growth of control cells was markedly re-
duced at 150 nM and nearly absent at 300 nM of Ara-C,
LV.SFFV.CDD transduced cells were completely protected
from Ara-C toxicity at both dose levels investigated
(Fig. 3b, Additional file 4: Figure S4B). Next, lin− cells were
transduced with LV.SFFV.CDD.2A.MDR1 lentiviral vector
and colony formation was studied following combined
daunorubicin/Ara-C challenge. LV.SFFV.CDD.2A.MDR1
gene-modified cells demonstrated a marked drug resistance
compared to LV.SFFV.GFP transduced control cells when
treated with a combination of 30 nM daunorubicin and 50
or 100 nM Ara-C. Less than 50 % of surviving colonies
were observed in control cells with the 30/50 combination
and this was even further reduced when Ara-C doses were
increased to 100 nM (Fig. 3c, Additional file 4: Figure S4C).
In contrast, more than 86 % of LV.SFFV.CDD.2A.MDR1
gene-modified clonogenic progenitor cells survived at
the 30/50 and 78 % at the 30/100 dose level,
highlighting the profound protection conferred by the
Fig. 1 Lentiviral vectors (LV) for transgenic MDR1 and CDD expression. 3rd generation self-inactivating (SIN) lentiviral vectors containing
(a) codon-optimized human MDR1-cDNA, (b) human CDD-cDNA, (c) human CDD-cDNA linked via porcine teschovirus-1 (P2A) sequence to
human codon-optimized MDR1 or (d) enhanced green fluorescent protein (GFP)-cDNA. All vectors carry a spleen focus forming virus (SFFV) promoter
and bicistronic vectors in A-C contain an internal ribosomal entry site (IRES) followed by green- or red fluorescent protein cDNA (GFP and dtomato).
LV vectors contain 5′ and 3′ long terminal repeats with SIN deletion in the U3 region (LTRs, ΔU3, R, U5), splice donor (SD) and splice acceptor (SA) sites,
the post-transcriptional regulatory element of woodchuck hepatitis virus (wPRE), a central polypurine tract (cPPT), the Rev responsive element (RRE)
and an extended encapsidation signal (Ψ) including the 5′ region of gag (ΔGA)
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Fig. 3 Chemoprotection of primary murine hematopoietic progenitor cells genetically engineered with MDR1 and CDD. Gene-modified lin−
hematopoietic progenitor cells were applied to a clonogenic progenitor assay. a LV.SFFV.MDR1 as well as LV.SFFV.GFP gene-modified cells
were treated with daunorubicin monotherapy (n = 3), (b) LV.SFFV.CDD as well as LV.SFFV.GFP transduced cells were treated with Ara-C
monotherapy (n= 3) and (c) LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated with daunorubicin/Ara-C combination therapy
(n= 4). Data are presented as mean ± SEM; *p≤ 0.05/** p≤ 0.01 denote significant differences compared to LV.SFFV.GFP control (calculated by ANOVA)
Fig. 2 Chemoprotection of murine 32D cells following transgenic expression of MDR1 and CDD. 32D cells transduced with LV.SFFV.MDR1,
LV.SFFV.CDD or LV.SFFV.GFP lentiviral vectors were treated with (a) daunorubicin (n = 3–11) or (b) Ara-C (n = 4–10) monotherapy. 32D cells genetically
modified with two drug resistance genes either by co-transduction of LV.SFFV.MDR1 and LV.SFFV.CDD or by LV.SFFV.CDD.2A.MDR1 transduction as well
as LV.SFFV.GFP transduced cells were treated with (c) daunorubicin (n = 3–11), (d) Ara-C (n = 4–11) monotherapy or (e) combined daunorubicin/Ara-C
therapy (n = 3–12). Data are presented as mean ± SD; *p ≤ 0.05/**p ≤ 0.01 denote significant differences compared to untransduced control
(calculated by ANOVA)
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LV.SFFV.CDD.2A.MDR1 vector to hematopoietic progen-
itors in the context of combined anthracycline/nucleoside
analog treatment (Fig. 3c).
These results were confirmed when transduced lin−
cells were exposed to the cytotoxic drugs in suspension
cultures in the presence of IL-3 and G-CSF for three days.
Again LV.SFFV.MDR1 transduced cells were significantly
protected from daunorubicin (Fig. 4a, Additional file 4:
Figure S4D) and LV.SFFV.CDD gene-modified cells from
Ara-C (Fig. 4b, Additional file 4: Figure S4E) while
simultaneous expression of MDR1 and CDD from the
LV.SFFV.CDD.2A.MDR1 yielded protection from both
agents (Fig. 4c, d, Additional file 4: Figure S4F). In compari-
son to LV.SFFV.GFP transduced control cells, proportions
of live cells at the end of the experiment were significantly
increased following daunorubicin (2.4-4.2-fold for
LV.SFFV.MDR1 and 3-4-fold for LV.SFFV.CDD.2A.MDR1)
as well as Ara-C (3.3-fold for LV.SFFV.CDD and 2.2-fold
for LV.SFFV.CDD.2A.MDR1) application. Again, gen-
etic modification with the LV.SFFV.CDD.2A.MDR1
vector revealed a significant protection from combined
daunorubicin/Ara-C application (Fig. 4e).
Marked selection of CTX-R gene-modified cells following
chemotherapy application
Notably, considerable in vitro enrichment of CTX-R
gene-modified cells upon cytotoxic drug treatment was
observed in the latter studies. While gene-marking in
non-treated lin− cells in cytokine supported suspension
cultures ranged from 1 to 9 % for the LV.SFFV.MDR1,
and from 5 to 6 % for the LV.SFFV.CDD vector, these
were increased to 67-80 % (LV.SFFV.MDR1) and 56-
75 % (LV.SFFV.CDD) after culture in the presence of
45 nM daunorubicin and 500 nM Ara-C, respectively
(Additional file 5: Table S1). For the LV.SFFV.MDR1 vec-
tor this constitutes an 11.0 ± 1.9 and 13.2 ± 1.2 -fold en-
richment of transduced cells of in the presence of 30 and
45 nM daunorubicin, respectively (Fig. 5d). Similar results
were generated for the LV.SFFV.CDD construct with a
6.5 ± 2.6 and 11.8 ± 1.1 -fold enrichment in the presence
of 300 and 500 nM of Ara-C (Fig. 5e).
Marked and significant in vitro selection also was ob-
served for the LV.SFFV.CDD.2A.MDR1 construct. While
3-20 % of gene marking were observed following trans-
duction this was increased to 36-84 % respective 23-
66 % following exposure to daunorubicin or Ara-C alone
(Fig. 5d, e and Additional file 5: Table S1) and to 59-
85 % upon combined drug application. This correlated
to a 10.7 ± 4.4 (30/300) and 7.7 ± 2.8 -fold (45/300) en-
richment upon treatment with the two daunorubicin/
Ara-C combinations (Fig. 5f ). No enrichment has been
observed in LV.SFFV.GFP transduced control cells. Taken
together, these data clearly show an enhanced survival and
substantial in vitro selection of CTX-R gene-modified cells
upon cytotoxic drug treatment applied as single agent
as well as combination therapy.
Discussion
Transplantation of ex vivo CTX-R gene modified
hematopoietic stem-and progenitor cells may reduce
Fig. 4 Enhanced survival of CTX-R gene-modified primary murine hematopoietic cells during myeloid differentiation. Non-sorted genetically
modified lin− cells were subjected to myeloid differentiation in suspension culture in the presence of cytotoxic drugs. a LV.SFFV.MDR1 as well as
LV.SFFV.GFP gene-modified cells were treated with daunorubicin monotherapy (n= 4–7), and (b) LV.SFFV.CDD as well as LV.SFFV.GFP transduced cells were
treated with Ara-C monotherapy (n= 7). LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP were treated with (c) daunorubicin (n= 6), (d) Ara-C monotherapy
(n= 7–12) or (e) daunorubicin/Ara-C combination therapy (n= 5–6). Data are presented as mean ± SD; *p≤ 0.05/** p≤ 0.01 denote significant differences
compared to LV.SFFV.GFP control (calculated by ANOVA)
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cytotoxic drug induced myelotoxicity and allow for
dose-intensified or prolonged chemotherapy application.
Towards this objective, we have generated lentiviral vec-
tors expressing MDR1 as well as CDD to genetically en-
gineer murine hematopoietic cells for increased inherent
resistance to anthracycline- and nucleoside-analogue-
type cytotoxic drugs. Utilizing these vectors, we demon-
strate highly efficient chemoprotection as well as in vitro
enrichment of transduced hematopoietic cells in the
context of Ara-C as well as anthracycline application.
Moreover, and of particular importance, dual expression
of the CDD as well as the MDR1 transgene conferred
significant cellular resistance to combined nucleoside
analogue/anthracycline application.
Transgenic expression of CDD successfully conferred
resistance to Ara-C in myeloid 32D as well as primary
murine bone marrow cells. The degree of Ara-C resist-
ance achieved was comparable to that described with
LTR-driven γ-retroviral vectors in the past [30, 32, 35, 41].
Similarly, resistance to MDR1 associated drugs conferred
to 32D and primary hematopoietic cells by transgenic
MDR1 (over)expression was in the same range as reported
in most studies before [10–12]. On this ground we also
would expect similar in vivo efficacy of our constructs as
previously demonstrated for –retroviral vectors in murine
or humanized transplant models [18, 19, 33, 34]. Most
importantly, however, effective protection from combined
Ara-C/anthracycline application by the CDD/MDR1 com-
bination was shown in our experiments demonstrating
the feasibility to functionally co-express both genes in
hematopoietic cells. Given that anti-cancer chemotherapy
usually is applied as a combination of multiple agents,
simultaneous transfer of CTX-R genes, represents a
logical strategy for myeloprotection, and particularly
combinations including MDR1 have been studied.
Combination partners have been, glutathione S-transferase
(GST), MGMT or mutDHFR to allow for additional pro-
tection against alkylators such as nitrosoureas, temozolo-
mide (MGMT), chlorambucil, melphalan (GST), as well as
folate antagonists [13, 14, 20, 42, 43]. Similarly, CDD has
been combined with GST [44] and mutDHFR [45–47] to
add nitrogen mustards and folate antagonists to the resist-
ance spectrum. In our attempt to transfer the protection
concept to AML and MDS treatment settings, we now for
the first time demonstrate the successful combination of
CDD and MDR1.
In our study, safety-optimized 3rd generation SIN lenti-
viral vectors were utilized. While effective myeloprotection
was observed for all constructs, transduction efficiency and
titers were reduced with vectors containing MDR1, most
likely due to the size of the transgene cassette. As this may
be problematic for in vivo applications, gene transfer effi-
cacy needs to be improved. Here, addition of transduction
enhancers, such as rapamycin or cylosporin A, engineering
Fig. 5 In vitro selection of CTX-R gene-modified primary murine hematopoietic cells during myeloid differentiation. Non-sorted genetically modified
lin− cells were treated with cytotoxic drugs in mIL-3/h-GCSF supported suspension culture. a-c Representative flow cytometric data are given to show
enrichment of gene-marked cells analyzed by GFP reporter gene expression (FL-1). d LV.SFFV.MDR1, LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP
gene-modified cells were treated with daunorubicin monotherapy (n = 3–7), and (e) LV.SFFV.CDD, LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP
transduced cells were treated with Ara-C monotherapy (n = 7–12). f LV.SFFV.CDD.2A.MDR1 as well as LV.SFFV.GFP gene-modified cells were treated
with daunorubicin/Ara-C combination therapy (n = 4–6). Data are presented as fold increase in % GFP+ cells (non-treated cells = 1) and mean ± SD are
given; *p≤ 0.05/**p≤ 0.01 denote significant differences compared to untreated cells with the same vector (calculated by ANOVA)
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of the vector surface phenotype, or suitable ex vivo
selection strategies prior to transplant may increase
efficacy [48–51]. Co-expression of MDR1 and CDD was
accomplished with co-transduction of cells with single
gene vectors (in case of 32D cells) or by using the
LV.SFFV.CDD.2A.MDR1 combination vector. In this
vector, CDD and MDR1 are linked via a porcine
teschovirus-1 (P2A) linker sequence that, in contrast to
internal ribosomal entry (IRES) sites, should result in
equimolar expression of both transgenes [52, 53]. In our
experiments however, LV.SFFV.CDD.2A.MDR1 transduc-
tion, though highly effective, resulted in moderately re-
duced Ara-C resistance compared to double-transduced or
LV.SFFV.CDD -transduced cells indicating reduced CDD
expression from the LV.SFFV.CDD.2A.MDR1 vector. In
this context, position dependency of transgene expression
resulting in altered protection levels recently was shown
for vectors combining MDR1 and MGMT via an F2A site.
In addition, the residual “2A” tag on the upstream CDD
protein may negatively influence transgene function [53].
In our study, efficient selection of CTX-R expressing
cells was demonstrated following cytotoxic drug admin-
istration. This may be of considerable relevance for the
clinical translation of our strategy, given the relative low
transduction levels achieved with our MDR1 vector
constructs so far. Though a myeloproliferative syndrome
has been described in mice transplanted with MDR1
gene-modified hematopoietic cells following extensive ex
vivo expansion, this almost certain was related to the
LTR-driven design of the γ-retroviral vector as well as the
applied culture conditions utilized in this study and has not
been reproduced with modern safety-improved vector
constructs [54]. Efficient selection of MDR1 gene-modified
cells convincingly has been demonstrated for murine as
well as human hematopoietic cells [18, 48, 55] and selection
also has been demonstrated for the CDD/Ara-C system in
vitro [32, 56] and in a murine transplant model [33].
Given the therapeutic efficacy of Ara-C/anthracycline
combinations in AML as well as high-risk MDS, com-
bined CDD/MDR1 gene-transfer as a clinical scenario
clearly is directed towards these disease entities. Here,
consolidation treatment of high-risk disease states (e.g.
second remission or even refractory disease) following
secondary transplantation can be envisioned as the pri-
mary scenario. In these highly unfavorable disease situa-
tions, the potential benefits of additional chemotherapy
given with few hematologic effects on disease outcome
as well as live quality would clearly offset the potential
genotoxic risks associated with the procedure. Moreover,
an inadvertent transduction of leukemic cells by the
CTX-R transgenes would be prevented by the allogeneic
setting. If proven effective and safe, myeloprotection by
the CDD/ MDR1 combination may have potential to im-
prove disease outcome in the elderly, especially following
alloHSCT employing reduced intensity conditioning regi-
men. Here the application of additional chemotherapy is
associated with increased hematotoxicity frequently
resulting in profound and long-lasting myelosuppression
and severe infectious complication. Due to its primarily
hematological side effects, at least at conventional doses,
cytarabine in the context of CDD/MDR1 induced mye-
loprotection may be applied even at enhanced doses
[57, 58], while dose-intensification of anthracyclines
will be limited by its cardiotoxicity [59].
Certainly safety constitutes a critical aspect also of
myeloprotective gene therapy approaches, and insertional
mutagenesis clearly represents a concern with the inte-
grating vectors. While the SFFV promoter used in this
study provides high level of transgene expression in hu-
man HSCs when incorporated into lentiviral vectors [60],
it is also associated with a higher genotoxic risk compared
to weaker physiological promoters [61]. In this context it
is reassuring that a markedly reduced genotoxic potential
has been demonstrated for novel generation SIN lentiviral
vectors such as the ones used in our studies [62]. More-
over, no genotoxic events such as profound clonal domin-
ance or leukemias have been encountered in the current
generation of hematopoietic gene therapy trial employing
safety-optimized y-retroviral or lentiviral SIN vectors
[63, 64]. This is of particular importance in the setting of
myeloprotective gene therapy, since insertional mutagen-
esis may give rise to drug-resistant leukemic cells. Incorp-
oration of suicide genes such as herpes simplex virus
thymidine kinase (HSV-TK) or inducible caspase 9 should
be considered as a fail-safe mechanism [65, 66].
Conclusions
In conclusion, we have demonstrated significant in vitro
protection and selection of CDD and MDR1 gene-modified
hematopoietic cells utilizing a safety-improved 3rd gener-
ation lentiviral gene transfer system as a first step towards
the concept of myeloprotective gene therapy in the context
of AML and MDS treatment. Now, the next step to further
provide evidence for the efficacy as well as safety of this ap-
proach will require in vivo studies in relevant animal system
including treatment studies in murine leukemia models.
Additional files
Additional file 1: Figure S1. Transgene expression of hMDR1 and hCDD
in gene-modified 32D cells. Transgene expression of gene-modified cells
was analyzed either before or after three day exposure to daunorubicin
[50nM], Ara-C [1000nM] or both cytotoxic drugs (daunorunicin/Ara-C:
[50nM/1000nM] combination). (A) hMDR1 mRNA expression is shown
in LV.SFFV.MDR1 and LV.SFFV.CDD.2A.MDR1 transduced 32D cells (n = 1,
technical replicates are shown; data are given relative to untransduced
(non-treated) control) and (B) expression of hCDD protein is shown for
LV.SFFV.CDD and LV.SFFV.CDD.2A.MDR1 gene-modified cells (n = 1; vinculin
used as loading control). (PDF 292 kb)
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Additional file 2: Figure S2. Multidrug-resistance phenotype of murine
MDR1 gene-modified 32D cells. 32D cells transduced with LV.SFFV.MDR1
or LV.SFFV.GFP lentiviral vector, and treated with (A) doxorubicin (n = 4–5)
or (B) paclitaxel (n = 4–5) or (C) etoposide (n = 4–5) monotherapy are
shown. Data are presented as mean ± SD; *p ≤ 0.05/**p ≤ 0.01 denote
significant differences compared to untransduced control (calculated
by ANOVA). (PDF 198 kb)
Additional file 3: Figure S3. Transgenic expression of CTX-R genes in
32D cells prevents cytotoxic drug-mediated cell cycle arrest. Cell proliferation
capacity of untransduced as well as CTX-R gene-modified cells was analyzed
by flow cytometric analysis following e670 labelling. The assay was performed
in the absence of cytotoxic drugs (upper row) as well as in the presence of
daunorubicin (second row), Ara-C (third row) or both drugs (last row). Cells
were analyzed three days post treatment (n= 1). (PDF 364 kb)
Additional file 4: Figure S4. Mock-transduced primary murine
hematopoietic cells are susceptible to cytotoxic drug treatment.
(A-C) Mock-transduced as well as FACS sorted CTX-R gene-modified
lin− hematopoietic progenitor cells were seeded in a clonogenic
assays in the absence or presence of cytotoxic drugs [n = 1; data are
given as mean (technical duplicates)]. (D-F) Mock-transduced and
non-sorted genetically modified lin− cells were treated with cytotoxic
drugs in mIL-3/h-GCSF supported suspension culture (n = 2–4; data
are given as mean ± SD). (PDF 157 kb)
Additional file 5: Table S1. In vitro selection of primary hematopoietic
gene-modified cells. Data for in vitro selection experiments are given as
% GFP+ cells (three days post treatment). (DOC 28 kb)
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